NCTN Adolescent and Young Adult (AYA) Cancer Trials Portfolio (Updated on 10/15/2026)

Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and the study information.

Newly Diagnosed Disease

Osteosarcoma (Pulmonary mets)
AOST2031

Osteosarcoma (High Grade)
AOST2032

Classical Hodgkin Lymphoma
AHOD2131

Invasive Breast Carcinoma (HR+/HER2-)
NRG-BR009 (OFSET)*^

Germ Cell Tumors
AGCT1531
AGCT1532

Precursor B-Lymphoblastic Leukemia (B-Cell ALL)
A041501*

Adrenocortical Carcinoma
A092204

Low-grade Astrocytoma
A072301

Rhabdomyosarcoma (Intermediate risk)
ARST2531

Nongerminomatous germ cell tumor of the CNS
ACNS2021

B-cell Acute Lymphoblastic Leukemia/ Acute Leukemia with Ambiguous Lineage – in Morphological CR1 (B-Cell ALL/ALAL)
S2507

Legend by Disease Types

- Green = Osteo-sarcoma
- Orange = Hodgkin Lymphoma
- Purple = Breast
- Yellow = Germ Cell Tumors
- Blue = B-Cell ALL
- Light Green = Adrenocortical Carcinoma
- Light Gray = Low-grade Astrocytoma
- Light Pink = Rhabdomyo-sarcoma
- Light Purple = CNS NGGCT
- Light Blue = B-Cell ALL/ ALAL

Note: * NRG-BR009 and A041501: Age 18 years and older; ^ NRG-BR009: COG is not directly participating.

NCTN Adolescent and Young Adult (AYA) Cancer Trials Portfolio (Updated on 10/15/2026)

Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and the study information.

Recurrent Disease

Precursor B-Lymphoblastic Leukemia (B-Cell ALL)

AALL1821

Precursor T-Lymphoblastic Leukemia/ Lymphoma (T-Cell ALL/LBL) - MRD

EA9213

Desmoplastic Small Round Cell Tumor

PEPN1924~

Osteosarcoma (Pulmonary mets)

AOST2031

Adrenocortical Carcinoma

A092204

Legend by Disease Types

Blue = B-Cell ALL	Green = Osteo-sarcoma	Light Orange = T-Cell ALL/LBL	Light Green = Adrenocortical Carcinoma	Light Yellow = DSRCT

Note: ~ PEPN1924: Open through the COG Pediatric Early Phase Clinical Trial Network (PEP-CTN) and patients must be enrolled at one of the PEP-CTN institutions.
Ref: https://dctd.cancer.gov/research/networks/pediatric

NCTN Adolescent and Young Adult (AYA) Cancer Trials (Open as of 10/15/2026)

Protocol Number	Phase	Protocol Title
A041501	III	A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
A072301	III	Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination with the IDH Inhibitor Vorasidenib vs Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas
A092204	II	A Phase II Study of Cabozantinib in Combination with Cemiplimab (REGN2810) (Cabo-Cemiplimab (REGN-2810)) Versus Cabozantinib Alone in Adolescents and Adults with Advanced Adrenocortical Cancer
AALL1821	II	A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse
ACNS2021	II	A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
AGCT1531	III	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
AGCT1532	III	A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Germ Cell Tumors
AHOD2131	III	A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
AOST2031	III	A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
AOST2032	II/III	A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
ARST2531	III	A Randomized Phase 3 Study to Compare VAC (Higher Cyclophosphamide Dose and Intensity) Versus VAC/VI (Lower Cyclophosphamide Dose and Intensity) Plus Maintenance Therapy in Patients with Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma
EA9213	II	A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL)
NRG-BR009	III	A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score </= 25 (OFSET)
PEPN1924	II	A Phase 1/2 Study of DS-8201a (NSC# 807708) in Children, Adolescents, or Young Adults with Recurrent Osteosarcoma, Wilms Tumor, and Desmoplastic Small round Cell Tumor
S2507	II	A Phase II Randomized Study of Blinatumomab with or Without Revumenib for Patients with KMT2A-Translocation B-Cell Acute Lymphoblastic Leukemia (ALL)/ Acute Leukemia with Ambiguous Lineage (ALAL) with Persistent Measurable Residual Disease (MRD)

This portfolio shows NCTN trials. For information about NCORP trials, please see: https://ncorp.cancer.gov/find-a-study/